Acute levercelnecrose bij gebruik van ketoconazol tijdens de behandeling van onychomycose

E P Van Puijenbroek, H J Metselaar, P H Berghuis, P E Zondervan, B H Stricker

    OnderzoeksoutputAcademicpeer review

    3 Citaten (Scopus)

    Samenvatting

    The imidazole derivative ketoconazole is approved in the Netherlands for treatment of local and systemic fungal infections. Despite the risk of major hepatic damage, this antimycotic drug is still being used in daily practice for the oral treatment of patients with onychomycosis. Since April 1986, 18 cases of relatively severe hepatic damage in the Netherlands were ascribed to the oral use of ketoconazole for the treatment of onychomycosis, skin infection or vaginal candidiasis. Given the potential risk for the patients concerned, ketoconazole should no longer be prescribed for relatively mild cosmetic disorders such as onychomycosis.

    Vertaalde titel van de bijdrageAcute hepatocytic necrosis during ketoconazole therapy for treatment of onychomycosis. National Foundation for Registry and Evaluation of Adverse Effects
    Originele taal-2Dutch
    Pagina's (van-tot)2416-2418
    Aantal pagina's3
    TijdschriftNederlands Tijdschrift voor de Geneeskunde
    Volume142
    Nummer van het tijdschrift44
    StatusPublished - 31-okt.-1998

    Citeer dit